Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...
University of Queensland researchers have developed a method to predict if a child is likely to develop sepsis and go into organ failure. Associate Professor Lachlan Coin from UQ's Institute for ...
A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient's blood vessels. Researchers from The University of Queensland and the Queensland Children's ...
The sepsis definition describes three elements: infection, the host response and life-threatening organ dysfunction. Diagnosis is made based on myriad signs and symptoms, and although infection ...
The North Wales community is rallying around Peter Atkinson and his family as he recovers from necrotizing fasciitis, which ...
A simple blood test can tell doctors when it is safe to stop antibiotics in patients recovering from sepsis, a review led by ...
– Final Analysis Comparing 10 Allocetra TM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly ...
Sobi to advance Gamifant in interferon-gamma-driven sepsis based on EMBRACE topline data: Stockholm Friday, January 9, 2026, 11:00 Hrs [IST] Sobi, a global biopharma company, anno ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback